Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 448 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo sugar capsules Clear all
Completed Phase 2 Interventional

Managing Opioid Related Sleep Apnea With Acetazolamide

NCT06043830
View directory record Official record
Conditions
Sleep-Disordered Breathing, Obstructive Sleep Apnea, Central Sleep Apnea, Chronic Pain, Opioid Use
Interventions
Acetazolamide, Placebo
Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 5, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional

A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections

NCT06940622
View directory record Official record
Conditions
Recurrent UTIs, Recurrent Urinary Tract Infections, Recurrent Urinary Tract Infections in Women, Recurrent Urinary Tract Infection, Cystitis Recurrent, Cystitis Chronic, UTI, UTI - Urinary Tract Infection, UTI - Lower Urinary Tract Infection
Interventions
D-Mannose, Placebo
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years to 85 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 5, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Drug Discrimination in Methadone-Maintained Humans Study 2

NCT00733239
View directory record Official record
Conditions
Opioid Dependence
Interventions
2-4 of the drugs listed below
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Oct 5, 2026, 5:15 AM EDT
Completed Early Phase 1 Interventional

Doxazosin an a1 Antagonist for Alcohol Dependence

NCT01437046
View directory record Official record
Conditions
Alcohol Dependence, Anxiety
Interventions
Doxazosin, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Oct 5, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease

NCT01590888
View directory record Official record
Conditions
Huntington Disease
Interventions
PBT2, Placebo
Drug
Lead sponsor
Prana Biotechnology Limited
Industry
Eligibility
25 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
14
States / cities
San Diego, California • Englewood, Colorado • Farmington, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 5, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of CX157 (TriRima) for the Treatment of Depression

NCT00739908
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CX157 (TriRima), Placebo
Drug
Lead sponsor
CeNeRx BioPharma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Birmingham, Alabama • Beverly Hills, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Oct 5, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Bexarotene in Preventing Breast Cancer in Women at Genetic Risk

NCT00055991
View directory record Official record
Conditions
Breast Cancer
Interventions
bexarotene
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 5, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia

NCT01793935
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Sensoril®, Placebo
Drug
Lead sponsor
K.N. Roy Chengappa
Other
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Oct 5, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC)

NCT00943176
View directory record Official record
Conditions
Fatigue, Primary Biliary Cirrhosis
Interventions
Modafinil
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Oct 5, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE

NCT02258074
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Nicotinamide, Lanthanum Carbonate, Placebo (for Nicotinamide), Placebo (for lanthanum carbonate)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 5, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia

NCT00158223
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Pimozide, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
New York, New York • W. Brentwood, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 5, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP)

NCT05951023
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Eszopiclone 2 mg, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 5, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1

NCT01406873
View directory record Official record
Conditions
Myotonic Dystrophy
Interventions
Mexiletine, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 5, 2026, 5:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

NCT02319837
View directory record Official record
Conditions
Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Interventions
Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
77
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 5, 2026, 5:15 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress

NCT02432339
View directory record Official record
Conditions
Psychological Stress, Hypertension, Renal
Interventions
mycophenolate mofetil (MMF), Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 5, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Topiramate to Aid Smoking Cessation in Alcohol Dependent Men

NCT00802412
View directory record Official record
Conditions
Nicotine Dependence, Alcohol Dependence
Interventions
Topiramate, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years · Male only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 5, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks

NCT01218802
View directory record Official record
Conditions
HIV Infections, Heart Disease
Interventions
Rosuvastatin 10 mg. daily for 96 weeks, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Oct 5, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity

NCT01065571
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
carrageenan, dietary intervention with no-carrageenan diet
Dietary Supplement · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 5, 2026, 5:15 AM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids

NCT00735553
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 5, 2026, 5:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Test the Use of Duloxetine for Pain in MS

NCT00457730
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 5, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

NCT05726292
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Relacorilant, Enzalutamide, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy
Drug · Other · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Chicago, Illinois • Evanston, Illinois • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 5, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Minocycline Study in Pancreatic Cancer Patients

NCT01693523
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Minocycline, Placebo, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 5, 2026, 5:15 AM EDT
Not listed Not applicable Interventional

Supplemental Adjuvants for Intracellular Nutrition and Treatment

NCT00893724
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions
Neutral pills with no medicinal effect, Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals, Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline
Drug · Dietary Supplement
Lead sponsor
Mid-Atlantic Retina Consultations, Inc.
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 5, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction

NCT01516346
View directory record Official record
Conditions
Heart Failure, Congestive Heart Failure
Interventions
Isosorbide Dinitrate, Isosorbide Dinitrate + Hydralazine, Placebo
Drug
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 5, 2026, 5:15 AM EDT